Nitric Oxide Synthase Brain – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) – Pipeline Review, H1 2020’, provides in depth analysis on Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Cardiovascular, Infectious Disease, Oncology and Respiratory under development targeting Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope


– The report provides a snapshot of the global therapeutic landscape for Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39)

– The report reviews Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics and enlists all their major and minor projects

– The report assesses Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Eli Lilly and Co

NeurAxon Pharma Inc

Neurophyxia BV

SalubRx Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC

1.14.13.39) - Overview

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC

1.14.13.39) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC

1.14.13.39) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC

1.14.13.39) - Companies Involved in Therapeutics Development

Eli Lilly and Co

Neurophyxia BV

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC

1.14.13.39) - Drug Profiles

2-Iminobiotin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IC-87201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NXN-188 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NXN-462 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NXN-677 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBX-413 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBX-613 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBX-677 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBX-774 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NOS for Neurodegenerative Diseases and Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC

1.14.13.39) - Dormant Products

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC

1.14.13.39) - Product Development Milestones

Featured News & Press Releases

Aug 31, 2015: Formulation patent granted in US, China, Australia and New Zealand

Jul 31, 2015: Neurophyxia Provides Update on Phase II study of 2-IB

Sep 30, 2014: Neurophyxia Provides Update on Phase II Clinical Study of 2-Iminobiotin

Oct 15, 2012: Indiana University Scientists Identify New Compound That Could Prevent Post-Traumatic Stress Disorder

Feb 29, 2012: Neurophyxia Provides Update on 2-Iminobiotin

Jun 30, 2011: Neurophyxia Announces Completion of Phase I Study

Oct 31, 2010: NeurAxon Reports NXN-188 Phase II Data Demonstrates Efficacy In Acute Migraine

Jun 30, 2010: Neurophyxia Provides Update on Cinical Study of 2-Iminobiotin

Jan 31, 2010: Neurophyxia Receives Orphan Drug Designation in Europe for 2-IB

Feb 28, 2009: Neurophyxia Receives Orphan Drug Designation from FDA for 2-Iminobiotin

Oct 27, 2008: NeurAxon's NXN-188 Names One Of 10 Most Promising Neuroscience Projects

Sep 30, 2008: Neurophyxia Provides Update on Pre-Cinical Study of 2-Iminobiotin

Sep 05, 2008: NeurAxon’s NXN-188 Demonstrates Pain Relief In Migraine with Aura

Aug 14, 2007: NeurAxon Announces Positive Phase 1 Trial Data On NXN-188 For Migraine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indication, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Eli Lilly and Co, H1 2020

Pipeline by NeurAxon Pharma Inc, H1 2020

Pipeline by Neurophyxia BV, H1 2020

Pipeline by SalubRx Therapeutics Inc, H1 2020

Dormant Projects, H1 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports